The earnings call reflects a generally positive outlook with significant revenue growth driven by the biologics segment, improved margins, and successful product launches, alongside strategic noncore asset sales. However, challenges remain in the hardware segment and licensing revenue uncertainty.

Company Guidance -

Q3 2025

During the call, Xtant Medical provided several key metrics and guidance updates for the second quarter of fiscal year 2025. The company reported total revenue of $35.4 million, an increase of nearly 18% compared to the same period in 2024, with biologics growing more than 20%. It highlighted a gross margin improvement to 68.6% from 62.1% in 2024, driven by a favorable sales mix and improved production efficiency. Operating expenses decreased to $19.7 million, making up 55.5% of total revenue, down from 71.9% the previous year. The net income was reported at $3.5 million, or $0.02 per share, compared to a net loss of $3.9 million in 2024. Adjusted EBITDA was $6.9 million, a significant improvement from a loss of $0.6 million in the prior year. The company also raised its full-year revenue guidance to between $131 million and $135 million, reflecting growth of 11% to 15% over 2024, up from the previous guidance of $127 million to $131 million. This updated outlook does not account for the pending sale of noncore assets to Companion Spine, which is expected to bring in approximately $19.2 million in proceeds.

Strong Revenue Growth

Total revenue for the second quarter of 2025 was $35.4 million, representing an 18% increase compared to the same period in 2024.

Biologics Performance

Biologics revenue grew more than 20% over the second quarter of 2024, driven by new product launches and a sharpened focus on this business segment.

Gross Margin Improvement

Gross margin for Q2 2025 improved to 68.6% from 62.1% in the same period in 2024, driven by favorable sales mix and improved production efficiency.

Positive Net Income and EBITDA

Achieved a net income of $3.5 million or $0.02 per share compared to a net loss of $3.9 million in Q2 2024. Adjusted EBITDA for Q2 2025 was $6.9 million compared to an adjusted EBITDA loss of $0.6 million in Q2 2024.

Full Year Revenue Guidance Raised

Full year 2025 revenue guidance was increased to a range of $131 million to $135 million, representing growth of approximately 11% to 15% over 2024.

Successful New Product Launches

Launched OsteoFactor Pro and Trivium, enhancing the biologics product portfolio and supporting growth in orthobiologic categories.

Sale of Noncore Assets

Entered agreement to sell certain noncore assets for approximately $19.2 million, allowing focus on core biologics platform and debt reduction.

Xtant Medical Holdings (XTNT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

XTNT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	>-0.01 / -	-0.04	―	―	―
Aug 12, 2025	2025 (Q2)	-0.01 / -0.09	-0.03	-213.33% (-0.06)	―
May 12, 2025	2025 (Q1)	>-0.01 / 0.28	-0.03	1030.00% (+0.31)	―
Mar 06, 2025	2024 (Q4)	-0.01 / -0.02	-0.03	33.33% (<+0.01)	―
Nov 12, 2024	2024 (Q3)	-0.03 / -0.04	0.07	-157.14% (-0.11)	―
Aug 08, 2024	2024 (Q2)	-0.02 / -0.03	-0.02	-50.00% (>-0.01)	―
May 15, 2024	2024 (Q1)	- / -	-0.02	―	―
Apr 01, 2024	2023 (Q4)	-0.02 / -0.03	-0.02	-50.00% (>-0.01)	―
Nov 09, 2023	2023 (Q3)	-0.01 / 0.07	-0.025	380.00% (+0.10)	―
Aug 01, 2023	2023 (Q2)	-0.02 / -0.02	-0.02	0.00% (0.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

XTNT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$0.59	$0.67	+13.56%
May 12, 2025	$0.52	$0.60	+15.38%
Mar 06, 2025	$0.48	$0.46	-4.17%
Nov 12, 2024	$0.54	$0.47	-12.96%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Xtant Medical Holdings Inc (XTNT) report earnings?

Xtant Medical Holdings Inc (XTNT) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Xtant Medical Holdings Inc (XTNT) earnings time?

Xtant Medical Holdings Inc (XTNT) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is XTNT EPS forecast?

XTNT EPS forecast for the fiscal quarter 2025 (Q3) is >-0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing